(Q38675014)

5 September 2017

title

Dimethyl Fumarate: A Review in Relapsing-Remitting MS. (English)

1 reference

5 September 2017

1

Emma D Deeks

1 reference

5 September 2017

publication date

21 December 2015

1 reference

5 September 2017

1 reference

5 September 2017

volume

76

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

243-254

1 reference

Immunology and oxidative stress in multiple sclerosis: clinical and basic approach.

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Oral disease-modifying therapies for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effects of dimethyl fumarate on neuroprotection and immunomodulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

BG-12 in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

DMF, but not other fumarates, inhibits NF-κB activity in vitro in an Nrf2-independent manner.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Progressive multifocal leukoencephalopathy: new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0528-1

Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

21 January 2018

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE)

1 reference

12 December 2020

PML in a patient with lymphocytopenia treated with dimethyl fumarate

1 reference

12 December 2020

Fumarates Promote Cytoprotection of Central Nervous System Cells against Oxidative Stress via the Nuclear Factor (Erythroid-Derived 2)-Like 2 Pathway

1 reference

12 December 2020

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

1 reference

12 December 2020

Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study

1 reference

12 December 2020

10.1007/S40265-015-0528-1

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1030041356

0 references

1 reference